EN | DE
Researcher in Laboratory © HIPS

Dr Mostafa Hamed

About

Dr. Mostafa Hamed is a postdoctoral researcher at the Helmholtz institute for Pharmaceutical Research Saarland (HIPS) in the department of Drug Design and Optimization. Dr. Hamed works in the field of medicinal chemistry with focus in the design and optimization of novel antiinfective and antivirulence agents. 
Dr. Hamed studied pharmacy at Misr University for Science and Technology, Egypt and received his Master degree in medicinal chemistry from Cairo University. In 2013, he received his PhD in medicinal chemistry from Saarland University. 


2024

Two natural compounds as potential inhibitors against the Helicobacter pylori and Acinetobacter baumannii IspD enzymes

Chen X, Zhao H, Wang C, Hamed M, Shang Q, Yang Y, Diao X, Sun X, Hu W, Jiang X, …, Wu D, Zhuang J (2024)

Int. J. Antimicrob. Agents 63 (5)DOI: 10.1016/j.ijantimicag.2024.107160

Discovery and optimization of thiazole-based quorum sensing inhibitors as potent blockers of Pseudomonas aeruginosa pathogenicity

Abdelsamie A, Hamed M, Schütz C, Röhrig T, Kany A, Schmelz S, Blankenfeldt W, Hirsch A, Hartmann R, Empting M (2024)

Eur. J. Med. Chem. 276DOI: 10.1016/j.ejmech.2024.116685

Hit optimization by dynamic combinatorial chemistry on Streptococcus pneumoniae energy-coupling factor transporter ECF-PanT

Exapicheidou I, Shams A, Ibrahim H, Tsarenko A, Backenköhler M, Hamed M, Diamanti E, Volkamer A, slotboom d, Hirsch A (2024)

Chem. Commun. 60 (7): 870-873DOI: 10.1039/D3CC04738E

Development and evaluation of 2,4-disubstituted-5-aryl pyrimidine derivatives as antibacterial agents

Khalifa H, Rasheed S, Haupenthal J, Herrmann J, Mandour Y, Abadi A, Engel M, Müller R, Hirsch A, Abdel-Halim* M, Hamed* M (2024)

Archiv der PharmazieDOI: 10.1002/ardp.202300656

2023

Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle

Hamed M, Abdelsamie A, Rox K, Schütz C, Kany A, Röhrig T, Schmelz S, Blankenfeldt W, Arce-Rodriguez A, Borrero-de Acuña J, …, Hartmann R, Empting M (2023)

Adv. Sci. (Online)DOI: 10.1002/advs.202204443

2022

Design, Synthesis, Antimicrobial Activity, and Molecular Docking of Some New Diclofenac Derivatives

Tolba M, Hamed M, Sayed M, Kamal El-Dean A, Abdel-Mohsen S, Ibrahim O, Elgaher W, Hirsch A, Saddik A (2022)

Polycyclic Aromatic Compounds: 1-16DOI: 10.1080/10406638.2022.2102661

Structure-Guided Optimization of Small-Molecule Folate Uptake Inhibitors Targeting the Energy-Coupling Factor Transporters

Kiefer A, Bousis S, Hamed M, Diamanti E, Haupenthal J, Hirsch A (2022)

J. Med. Chem.DOI: 10.1021/acs.jmedchem.1c02114

Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors

Hamdy J, Emadeldin N, Hamed M, Frakolaki E, Katsamakas S, Vassilaki N, Zoidis G, Hirsch A, Abdel-Halim M, Abadi A (2022)

Pharmaceuticals 15 (5)DOI: 10.3390/ph15050632

Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Modification of the benzenoid part

Megahed S, Rasheed S, Herrmann J, El-Hossary E, El-Shabrawy Y, Abadi A, Engel M, Müller R, Abdel-Halim M, Hamed M (2022)

Bioorg Med Chem Lett 59DOI: 10.1016/j.bmcl.2022.128531

2021

New PqsR Inverse Agonist

Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)

New PqsR Inverse Agonist

Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)

Novel PqsR Inverse Agonists

Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)

Novel PqsR Inverse Agonists

Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)

Targeting the IspD Enzyme in the MEP Pathway: Identification of a Novel Fragment Class

Diamanti E, Hamed M, Lacour A, Bravo P, Illarionov B, Fischer M, Rottmann M, Witschel M, Hirsch A (2021)

ChemMedChemDOI: 10.1002/cmdc.202100679

Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier

Abdallah M, Hamed M, Frakolaki E, Katsamakas S, Vassilaki N, Bartenschlager R, Zoidis G, Hirsch A, Abdel-Halim M, Abadi A (2021)

European journal of medicinal chemistryDOI: 10.1016/j.ejmech.2021.114034

Expanding the Myxochelin Natural Product Family by Nicotinic Acid Containing Congeners

Frank N, Széles M, Akone S, Rasheed S, Hüttel S, Frewert S, Hamed M, Herrmann J, Schuler S, Hirsch A, Müller R (2021)

Molecules 26 (16)DOI: 10.3390/molecules26164929

A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms

Schütz C, Ho D, Hamed M, Abdelsamie A, Röhrig T, Herr C, Kany A, Rox K, Schmelz S, Siebenbürger L, …, Lehr C, Empting M (2021)

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (12)DOI: 10.1002/advs.202004369

2020

Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics

Elgaher W, Hamed M, Baumann S, Herrmann J, Siebenbürger L, Krull J, Cirnski K, Kirschning A, Brönstrup M, Müller R, Hartmann R (2020)

Chem. Eur. J. 26 (32): 7219-7225DOI: 10.1002/chem.202000117

Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy

Testolin G, Cirnski K, Rox K, Prochnow H, Fetz V, Grandclaudon C, Mollner T, Baiyoumy A, Ritter A, Leitner C, …, Müller R, Brönstrup M (2020)

Chemical Science 11 (5): 1316-1334DOI: 10.1039/C9SC04769G

Novel PqsR Inverse Agonists

Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2020)

Patent (EP20150119)

2015

Novel PqsR Inverse Agonists

Hamed M (2015)

Patent (EP 201523196)

Synthesis and biological evaluation of cystobactamid 507: a bacterial topoisomerase inhibitor from Cystobacter sp

Moreno M, Elgaher W, Herrmann J, Schläger N, Hamed M, Baumann S, Müller R, Hartmann R, Kirschning A (2015)

Synlett 26 (9): 1175-1178DOI: 10.1055/s-0034-1380509